Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TriSalus Life Sciences ( (TLSI) ) has issued an update.
On May 14, 2026, TriSalus Life Sciences, Inc. held its Annual Meeting of Stockholders, with 67.9% of outstanding common shares represented. Stockholders elected Mary Szela and Gary Gordon to three-year terms on the board ending in 2029 and ratified the appointment of Grant Thornton, LLP as the independent registered accounting firm for the 2026 fiscal year.
Investors also approved, on an advisory basis, a three-year frequency for future stockholder advisory votes on named executive officer compensation, and the board subsequently adopted this three-year schedule. In addition, stockholders endorsed the compensation of the company’s named executive officers, signaling support for current governance and executive pay practices.
The most recent analyst rating on (TLSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
The score is held down primarily by weak financial performance (steep TTM revenue decline, large ongoing losses, and continued cash burn with meaningful leverage). Technicals also weigh heavily given the pronounced downtrend versus all key moving averages and bearish momentum. Earnings-call positives (cash balance, strong gross margin, and clinical validation) partially offset, but guidance was revised down and regulatory timing uncertainty remains. Valuation is only middling (P/E ~33.5; no dividend support).
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
TriSalus Life Sciences, Inc. is a life sciences company operating in the healthcare and biotechnology sector. The company focuses on developing and commercializing therapies and related technologies, with its activities centered around advancing medical treatments for patients and creating value for stockholders in the biopharmaceutical market.
Average Trading Volume: 288,648
Technical Sentiment Signal: Sell
Current Market Cap: $280M
For detailed information about TLSI stock, go to TipRanks’ Stock Analysis page.